About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs
Bone morphogenetic protein 6 (BMP6) plays a crucial role in regulating ferromodulin expression, and targeting this pathway presents a promising therapeutic strategy [98]
doi:10.1053/jvet.2003.50066 10
Chen JH, Liu TY, Wu CW, et al
NADPH oxidase is the major source of placental superoxide in early pregnancy: association with MAPK pathway activation
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Kozlowski P, Raj D, Liu J, Lam C, Yung AC, Tetzlaff W